Gender Male
Investor Type Number of Exits
Dr. Hampl joined Great Point Partners’ Advisory Board in 2011 and is Co-Chairman of the Board of Directors our portfolio company Cytovance Biologics. He is also currently Executive Chairman of the Board of APP / Fresenius. Previously, Dr. Hampl was CEO of Eon Labs from 1996 to 2005 until the acquisition by Novartis at which time he became the
CEO of the Sandoz US-division of Novartis. During the period he was CEO of Eon, its revenue grew from $20 million to $435 million. Dr. Hampl earned a Ph.D. in Pharmaceutical Chemistry from the Ludwig Maximilian University of Munich, Germany, School of Pharmacy.
